Teleflex Completes Enrollment in BIOMAG-LL Freesolve Trial

what happened

TradingView, citing a Teleflex Incorporated press release distributed by BusinessWire, reported that the company had completed patient enrollment in the premarket BIOMAG-LL study. The trial is evaluating 35 mm and 40 mm Freesolve resorbable magnesium scaffolds in de novo coronary lesions measuring up to 38 mm.

The primary endpoint is target lesion failure, or TLF, at 12 months. Participants will be followed for as long as 60 months. The longer scaffold sizes are also included in BIOMAG-III, a pivotal trial being conducted in the United States and internationally.

Freesolve is not approved in the United States and is available in CE-mark markets. As a result, near-term U.S. revenue impact remains limited, while broader commercial prospects depend on trial results and regulatory decisions.

why it matters

The completed enrollment advances Teleflex’s clinical program for resorbable magnesium scaffolds. Twelve-month TLF results and longer-term follow-up may affect the prospects for expanding the portfolio, but enrollment alone does not represent product approval or confirm higher sales.

instruments